Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Intracerebral microinjection of interleukin-4/interleukin-13 reduces β-amyloid accumulation in the ipsilateral side and improves cognitive deficits in young amyloid precursor protein 23 mice.

Kawahara K, Suenobu M, Yoshida A, Koga K, Hyodo A, Ohtsuka H, Kuniyasu A, Tamamaki N, Sugimoto Y, Nakayama H.

Neuroscience. 2012 Apr 5;207:243-60. doi: 10.1016/j.neuroscience.2012.01.049. Epub 2012 Feb 7.

PMID:
22342341
2.

S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.

Zhang W, Zhang W, Li Z, Hao J, Zhang Z, Liu L, Mao N, Miao J, Zhang L.

Pharmacol Biochem Behav. 2012 Jan;100(3):361-9. doi: 10.1016/j.pbb.2011.09.012. Epub 2011 Oct 2.

PMID:
21993310
3.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072. Epub 2011 Apr 14.

PMID:
21513747
4.

IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia.

Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H.

J Immunol. 2008 Nov 1;181(9):6503-13.

5.

IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.

Browne TC, McQuillan K, McManus RM, O'Reilly JA, Mills KH, Lynch MA.

J Immunol. 2013 Mar 1;190(5):2241-51. doi: 10.4049/jimmunol.1200947. Epub 2013 Jan 30.

6.

Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits but do not form plaques.

Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, Koistinaho J, Bures J, Higgins LS.

Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14675-80. Epub 2001 Nov 27.

7.

Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid.

Fan R, Xu F, Previti ML, Davis J, Grande AM, Robinson JK, Van Nostrand WE.

J Neurosci. 2007 Mar 21;27(12):3057-63.

8.

Age-dependent cognitive decline in the APP23 model precedes amyloid deposition.

Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP.

Eur J Neurosci. 2003 Jan;17(2):388-96.

PMID:
12542676
9.

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ.

J Neurosci. 2012 Jul 11;32(28):9677-89. doi: 10.1523/JNEUROSCI.4742-11.2012.

10.

Telomere shortening reduces Alzheimer's disease amyloid pathology in mice.

Rolyan H, Scheffold A, Heinrich A, Begus-Nahrmann Y, Langkopf BH, Hölter SM, Vogt-Weisenhorn DM, Liss B, Wurst W, Lie DC, Thal DR, Biber K, Rudolph KL.

Brain. 2011 Jul;134(Pt 7):2044-56. doi: 10.1093/brain/awr133. Epub 2011 Jun 14.

PMID:
21672962
11.

Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice.

Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, Staufenbiel M, Jucker M.

J Neurosci. 2002 Jan 15;22(2):515-22.

12.

Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.

Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu GQ, Mucke L.

J Neurosci. 2009 Feb 18;29(7):1977-86. doi: 10.1523/JNEUROSCI.2984-08.2009.

13.

The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice.

Rijal Upadhaya A, Scheibe F, Kosterin I, Abramowski D, Gerth J, Kumar S, Liebau S, Yamaguchi H, Walter J, Staufenbiel M, Thal DR.

Acta Neuropathol Commun. 2013 Nov 18;1:77. doi: 10.1186/2051-5960-1-77.

14.
15.

Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels.

Timmer NM, van Dijk L, van der Zee CE, Kiliaan A, de Waal RM, Verbeek MM.

Neurobiol Dis. 2010 Oct;40(1):340-7. doi: 10.1016/j.nbd.2010.06.008. Epub 2010 Jun 22.

PMID:
20600909
16.

Environmental enrichment lessens cognitive decline in APP23 mice without affecting brain sirtuin expression.

Polito L, Chierchia A, Tunesi M, Bouybayoune I, Kehoe PG, Albani D, Forloni G.

J Alzheimers Dis. 2014;42(3):851-64. doi: 10.3233/JAD-131430.

PMID:
24961946
17.

Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease.

Kawahara K, Suenobu M, Ohtsuka H, Kuniyasu A, Sugimoto Y, Nakagomi M, Fukasawa H, Shudo K, Nakayama H.

J Alzheimers Dis. 2014;42(2):587-605. doi: 10.3233/JAD-132720.

PMID:
24916544
18.

Improving memory and decreasing cognitive impairment in Tg-APPswe/PSEN1dE9 mice with Aβ3-10 repeat fragment plasmid by reducing Aβ deposition and inflammatory response.

Ma Y, Li Y, Zong LX, Xing XN, Zhang WG, Cao YP.

Brain Res. 2011 Jul 11;1400:112-24. doi: 10.1016/j.brainres.2011.05.030. Epub 2011 May 23.

PMID:
21658683
19.

Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation.

Park SH, Kim JH, Bae SS, Hong KW, Lee DS, Leem JY, Choi BT, Shin HK.

Biochem Biophys Res Commun. 2011 May 20;408(4):602-8. doi: 10.1016/j.bbrc.2011.04.068. Epub 2011 Apr 22.

PMID:
21530492
20.

Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis.

Scullion GA, Kendall DA, Marsden CA, Sunter D, Pardon MC.

Neuropharmacology. 2011 Feb-Mar;60(2-3):223-34. doi: 10.1016/j.neuropharm.2010.09.002. Epub 2010 Sep 17.

PMID:
20850464

Supplemental Content

Support Center